Abstract
As there is little evidence of the efficacy of 25-hydroxyvitamin D3 (25-HCC) in reducing the risk of new fractures in osteoporotic women, we performed an open, prospective study with a follow-up of 1 yr in 58 females over 65 yr of age with osteoporosis and proximal femoral fractures. The patient group received 1 g calcium per day and 10 640 IU 25-HCC per week, while the control group received 1 g calcium daily. Biochemical markers of bone remodelling, serum calcium and parathyroid hormone were determined. Bone mineral density was assessed in the lumbar spine and in the proximal femur by two methods. After 1 yr of treatment, 25-HCC corrected secondary hyperparathyroidism, increased urine calcium excretion, and increased bone mass in the femoral neck, but had no effect upon the appearance of new fractures.
Publication types
-
Clinical Trial
-
Controlled Clinical Trial
MeSH terms
-
Absorptiometry, Photon
-
Acid Phosphatase / blood
-
Aged
-
Aged, 80 and over
-
Alkaline Phosphatase / blood
-
Biomarkers
-
Bone Density / drug effects*
-
Calcifediol / administration & dosage*
-
Calcium / administration & dosage
-
Calcium / blood
-
Creatinine / blood
-
Female
-
Femoral Neck Fractures / drug therapy*
-
Femoral Neck Fractures / etiology
-
Femoral Neck Fractures / prevention & control
-
Follow-Up Studies
-
Humans
-
Isoenzymes / blood
-
Osteoporosis / complications
-
Osteoporosis / drug therapy*
-
Parathyroid Hormone / blood
-
Phosphorus / blood
-
Prospective Studies
-
Tartrate-Resistant Acid Phosphatase
-
Urea / blood
Substances
-
Biomarkers
-
Isoenzymes
-
Parathyroid Hormone
-
Phosphorus
-
Urea
-
Creatinine
-
Alkaline Phosphatase
-
Acid Phosphatase
-
Tartrate-Resistant Acid Phosphatase
-
Calcifediol
-
Calcium